Altay Therapeutics
vendor · www.altaytherapeutics.com
Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. With our current
About
Altay Therapeutics is a maker — it sells what it builds, with nothing priced here yet.
Nothing it sells has been priced into the catalogue yet — the company is here as a name the market uses, and the page will fill as its prices are read.
Every current figure
- Kind
- vendor
- Home
- http://www.altaytherapeutics.com